FDA advisory panel backs broader use of wellness peptide BPC-157 despite internal concerns

The FDA advisory committee voted Thursday to recommend loosening restrictions on BPC-157, a peptide popular among health and wellness enthusiasts for muscle repair, injury healing, metabolism support, and inflammation reduction.

Committee members highlighted the peptide's growing use and potential benefits, while some staff voiced concerns about safety data and regulatory oversight.

If the FDA adopts the panel's advice, the move could open the market to broader access and create significant commercial opportunities.